Payment overview · 2025
General Payments
$40.23
2 reported records · 2 companies
Healthcare provider profile · identity verified
James Blakeley Long, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · GLOUCESTER, VA · NPI 1689861635
Verified facts
What the public records show
CMS Open Payments records show James Blakeley Long, M.D. received $40.23 in general payments during 2025 across 2 reported records.
ABBVIE INC. accounted for 53.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 194 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $21.38 | 53.1% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.85 | 46.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $21.38 | 1 |
| Education | $18.85 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $21.38 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $21.38 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $18.85 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 194 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
55 | 16 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
194 | 44 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 527 | 150 |
| Atorvastatin Calcium | Atorvastatin Calcium | 430 | 122 |
| Amlodipine Besylate | Amlodipine Besylate | 427 | 130 |
| Lisinopril | Lisinopril | 412 | 115 |
| Losartan Potassium | Losartan Potassium | 353 | 100 |
| Levothyroxine Sodium | Levothyroxine Sodium | 290 | 79 |
| Metoprolol Succinate | Metoprolol Succinate | 271 | 69 |
| Trazodone Hcl | Trazodone Hcl | 263 | 64 |
| Furosemide | Furosemide | 225 | 74 |
| Gabapentin | Gabapentin | 214 | 69 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 199 | 51 |
| Jardiance | Empagliflozin | 194 | 44 |
| Pantoprazole Sodium | Pantoprazole Sodium | 190 | 59 |
| Metformin Hcl | Metformin Hcl | 180 | 53 |
| Hydrochlorothiazide | Hydrochlorothiazide | 174 | 52 |
| Omeprazole | Omeprazole | 162 | 43 |
| Simvastatin | Simvastatin | 157 | 44 |
| Tamsulosin Hcl | Tamsulosin Hcl | 149 | 44 |
| Potassium Chloride | Potassium Chloride | 133 | 41 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 116 | 40 |
| Metformin Hcl Er | Metformin Hcl | 113 | 31 |
| Glipizide | Glipizide | 112 | 33 |
| Prednisone | Prednisone | 111 | 78 |
| Fluticasone Propionate | Fluticasone Propionate | 106 | 31 |
| Allopurinol | Allopurinol | 105 | 29 |
| Eliquis | Apixaban | 104 | 27 |
| Sertraline Hcl | Sertraline Hcl | 95 | 26 |
| Famotidine | Famotidine | 93 | 26 |
| Alprazolam | Alprazolam | 92 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 91 | 24 |
| Pravastatin Sodium | Pravastatin Sodium | 88 | 24 |
| Montelukast Sodium | Montelukast Sodium | 86 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 85 | 23 |
| Doxycycline Hyclate | Doxycycline Hyclate | 78 | 60 |
| Tramadol Hcl | Tramadol Hcl | 76 | 28 |
| Atenolol | Atenolol | 73 | 20 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 72 | 22 |
| Trulicity | Dulaglutide | 71 | 16 |
| Alendronate Sodium | Alendronate Sodium | 70 | 14 |
| Celecoxib | Celecoxib | 67 | 16 |
| Finasteride | Finasteride | 64 | 20 |
| Azithromycin | Azithromycin | 62 | 58 |
| Diclofenac Sodium | Diclofenac Sodium | 62 | 14 |
| Spironolactone | Spironolactone | 62 | 20 |
| Cephalexin | Cephalexin | 60 | 38 |
| Meloxicam | Meloxicam | 60 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 60 | 15 |
| Fenofibrate | Fenofibrate Nanocrystallized | 56 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 55 | 19 |
| Synthroid | Levothyroxine Sodium | 55 | 16 |
| Baclofen | Baclofen | 53 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 53 | 15 |
| Glipizide Er | Glipizide | 53 | 16 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 52 | 43 |
| Bupropion Xl | Bupropion Hcl | 52 | 18 |
| Carvedilol | Carvedilol | 51 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 51 | 20 |
| Lorazepam | Lorazepam | 50 | 25 |
| Mounjaro | Tirzepatide | 50 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 47 | 15 |
| Xarelto | Rivaroxaban | 47 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 43 | 11 |
| Mirtazapine | Mirtazapine | 42 | 19 |
| Januvia | Sitagliptin Phosphate | 41 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 40 | 11 |
| Ezetimibe | Ezetimibe | 39 | 14 |
| Levetiracetam | Levetiracetam | 38 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 37 | 28 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 36 | 34 |
| Meclizine Hcl | Meclizine Hcl | 34 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 34 | 15 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 33 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 32 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 32 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 31 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 30 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 30 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 29 | suppressed |
| Clonazepam | Clonazepam | 29 | suppressed |
| Ondansetron Odt | Ondansetron | 28 | 19 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 27 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 27 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 27 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 26 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 26 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 25 | suppressed |
| Ozempic | Semaglutide | 25 | suppressed |
| Torsemide | Torsemide | 25 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 23 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 23 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 22 | suppressed |
| Amoxicillin | Amoxicillin | 21 | suppressed |
| Diazepam | Diazepam | 21 | suppressed |
| Methylprednisolone | Methylprednisolone | 21 | 20 |
| Nystatin | Nystatin | 21 | 15 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 20 | 15 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 20 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 19 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 18 | suppressed |
| Erythromycin | Erythromycin Base | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Nifedipine Er | Nifedipine | 18 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 18 | suppressed |
| Verapamil Er | Verapamil Hcl | 18 | suppressed |
| Acyclovir | Acyclovir | 17 | suppressed |
| Ketoconazole | Ketoconazole | 17 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 17 | 17 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 17 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | 14 |
| Pregabalin | Pregabalin | 16 | suppressed |
| Ramipril | Ramipril | 16 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 16 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | 14 |
| Hydrocortisone | Hydrocortisone | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Ciclopirox | Ciclopirox | 14 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Levofloxacin | Levofloxacin | 14 | 12 |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Folic Acid | Folic Acid | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $40.23 · 2 records | ABBVIE INC. | JARDIANCE, QULIPTA, UBRELVY | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error